Jiří Tomášek

机构：Masaryk Memorial Cancer Institute · ORCID：0000-0002-7635-9103

发表论文 256 篇 · 总被引 6174 次 · h-index 22

代表论文

• Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study (2023 · The Lancet · 被引 351)
• Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study (2024 · Journal of Clinical Oncology · 被引 177)
• Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT ‐4 lung subgroup analysis (2017 · Cancer Science · 被引 108)
• Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study (2018 · Annals of Oncology · 被引 66)
• Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours (2018 · Neuroendocrinology · 被引 55)
• Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study (2022 · Clinical Colorectal Cancer · 被引 31)